Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Detecting Unfaithful Chain-of-Thought via Circuit-Guided Internal-External Discrepancy
arXiv:2605.25603v1 Announce Type: new Abstract: Chain-of-thought (CoT) reasoning improves the problem-solving ability of large language models (LLMs), but generated reasoning traces may not faithfully reflect the model's actual decision process. Existing CoT unfaithfulness detectors mainly rely on external signals from generated rationales, such as textual plausibility or answer consistency, while overlooking evidence from the model's internal computation. Although recent circuit tracing method
-
cs.AI, q-bio.NC updates on arXiv.org
-
LiveMCP-101: Stress Testing and Diagnosing MCP-enabled Agents on Challenging Queries
arXiv:2508.15760v2 Announce Type: replace-cross Abstract: Tool calling has emerged as a critical capability for AI agents. In contrast to conventional tool calling frameworks that rely on static, provider-specific tool definitions, the Model Context Protocol (MCP) offers a unified interface to discover and invoke tools dynamically. However, there is a significant gap in benchmarking multi-step tasks using diverse MCP tools in realistic, dynamic scenarios. In this work, we present LiveMCP-101, a
LiveMCP-101: Stress Testing and Diagnosing MCP-enabled Agents on Challenging Queries
-
Omics In Lung
-
Integrative fragmentomic and mutational signature profile of plasma cfDNA for early lung cancer detection
NPJ Precis Oncol. 2026 Apr 15. doi: 10.1038/s41698-026-01416-y. Online ahead of print.ABSTRACTDetecting lung cancer effectively in the general population is essential for optimizing treatment outcomes and improving the 5-year survival rate. While low-dose computed tomography (LDCT) is the current standard, it has limitations in broader populations. We developed a blood-based multi-omics model using whole-genome cell-free DNA (cfDNA) features to distinguish lung cancer from non-cancer individuals
Integrative fragmentomic and mutational signature profile of plasma cfDNA for early lung cancer detection
NPJ Precis Oncol. 2026 Apr 15. doi: 10.1038/s41698-026-01416-y. Online ahead of print.
ABSTRACT
Detecting lung cancer effectively in the general population is essential for optimizing treatment outcomes and improving the 5-year survival rate. While low-dose computed tomography (LDCT) is the current standard, it has limitations in broader populations. We developed a blood-based multi-omics model using whole-genome cell-free DNA (cfDNA) features to distinguish lung cancer from non-cancer individuals. This study included 1600 patients and an equal number of non-cancer controls, divided into training and validation cohorts. The model achieved an area under the curve (AUC) of 95.59% for the training cohort and 95.74% for the validation cohort. The model consistently performed well across various cancer stages and histological subtypes. To further validate the performance of the model, an external validation cohort was utilized. Notably, it also effectively differentiated non-cancer samples from cancer samples in the external validation cohort, with 85.9% sensitivity and 94.78% specificity. Importantly, in simulated population screenings, our ctDNA assay outperformed both LDCT and a previously established method. This suggests its potential utility in wider lung cancer screening programs, possibly complementing the LDCT approach. In conclusion, our ctDNA assay emerges as a promising and highly sensitive tool for the early detection and categorization of lung cancer.
PMID:41986614 | DOI:10.1038/s41698-026-01416-y